Key result
Left ventricular hypertrophy in hypertensive patients undergoing PCI with drug-eluting stents was associated with a higher incidence of cardiac death over 8 years, although the primary composite endpoint of major cardiovascular events was not increased.
Why the study?
Does left ventricular hypertrophy increase the risk of adverse clinical outcomes in hypertensive patients who underwent successful percutaneous coronary intervention with drug-eluting stents?
Observational (n=1,704)
No
Does left ventricular hypertrophy increase the risk of adverse clinical outcomes in hypertensive patients who underwent successful percutaneous coronary intervention with drug-eluting stents?
Left ventricular hypertrophy is associated with a significantly higher risk of long-term cardiac death in hypertensive patients undergoing PCI with drug-eluting stents.
Answers are grounded in this paper and cite their sources.
LVH should not yet guide post-PCI management in hypertensives; leaves open independent cardiac death prediction and needs prospective confirmation.
Left ventricular hypertrophy (LVH) is associated with increased risk for vascular events and mortality. This study investigated 8-year clinical outcomes of hypertensive patients with LVH who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) compared with hypertensive patients without LVH.A total of 1704 consecutive hypertensive patients who underwent PCI from 2004 to 2014 were enrolled. We classified them into either the LVH group (n = 406) or the control group (without LVH, n = 1298). LVH was defined by LV mass index > 115 g/m in men and > 95 g/m in women. After propensity score matched (PSM) analysis, 2 PSM groups (366 pairs, n = 732, c-statistic = 0.629) were generated.For up to 8 years, the LVH group showed a higher incidence of cardiac death (4.4% vs 1.2%, log-rank P = .023, hazard ratio: 3.371, 95% confidence interval: 1.109-10.25; P = .032) compared with the control group. However, there were no significant differences between the 2 groups in the incidence of total death, myocardial infarction, revascularization, and major adverse cardiac events up to 8 years.LVH in hypertensive patients who underwent successful PCI with DES was associated with higher incidence of cardiac death up to 8 years of follow-up. More careful managements and clinical follow-up are needed and treatment strategies should specifically focus to target prevention and reversal of LVH in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) conducted an observational in Hypertension and coronary artery disease requiring percutaneous coronary intervention (n=1,704). Left ventricular hypertrophy vs. Without left ventricular hypertrophy was evaluated on Major adverse cardiac events (MACE) (HR 1.239, 95% CI 0.879-1.747, p=0.220). Left ventricular hypertrophy in hypertensive patients undergoing PCI with drug-eluting stents was associated with a higher incidence of cardiac death over 8 years, although the primary composite endpoint of major cardiovascular events was not increased.
Synapse has enriched 10 related papers. Consider them for comparative context: